Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087191 · ClinicalTrials.gov registry record · NA
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
A NA study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00087191: Clinical Trial NA study, sponsored by National Cancer Institute (NCI).
NCT00087191 is a NA study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087191, a NA study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor tissue. Photosensitizing drugs such as motexafin lutetium are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. Knowing the level of oxygen in tumor tissue and the level of motexafin lutetium absorbed by tumors and normal tissue may help predict the effectiveness of anticancer therapy
Interventions
- OTHER pharmacological study
- DRUG EF5
- DRUG motexafin lutetium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087191
The ClinicalTrials.gov registry entry for NCT00087191 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pharmacological study is the first listed.
NCT00087191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087191 about?
NCT00087191 is a clinical study titled "EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer". This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor tissue. Photosensitizing drugs...
What is the current status of trial NCT00087191?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2004-05.
What interventions are being tested in trial NCT00087191?
The interventions under investigation include: pharmacological study (OTHER), EF5 (DRUG), motexafin lutetium (DRUG).
Who is sponsoring clinical trial NCT00087191?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.